Cardio-Kidney-Metabolic Syndrome in Chronic Total Occlusion Percutaneous Coronary Intervention
Abstract Body (Do not enter title and authors here): Background Cardio-kidney-metabolic (CKM) syndrome, characterized by coronary artery disease, diabetes mellitus (DM), obesity, and chronic kidney disease (CKD), is linked to poor cardiovascular (CV) outcomes. Its impact on procedural complexity and outcomes of chronic total occlusion (CTO) percutaneous coronary intervention (PCI) remains unclear. Methods Our study included 9,133 CTO PCIs performed at 51 centers worldwide between 2012 and 2024. Procedural and angiographic characteristics were compared between patients with and without CKM syndrome. Multivariable logistic regression was used to evaluate the association of CKM syndrome with technical success and MACE. Results Patients who udnerwent CTO PCI were stratified into five groups: control (n=2,732), obesity (n=1,990), obesity + DM (n=1,739), obesity + CKD (n=1,200), and obesity + CKD + DM (CKM, n=1,472). Compared with the other groups, CKM patients had more CV risk factors, including prior myocardial infarction (control 40.8%, obesity 39.6%, obesity+DM 41.1%, obesity+CKD 44.6%, CKM 45.6%; p=0.002). Angiographic complexity increased across groups: moderate-to-severe calcification (control 38.4%, obesity 37.1%, obesity+DM 46.4%, obesity+CKD 46.0%, CKM 55.7%; p<0.001), moderate-to-severe proximal tortuosity (24.1%, 24.7%, 26.7%, 26.5%, 33.0%, respectively, p<0.001), and proximal cap ambiguity (32.9%, 35.2%, 34.1%, 37.2%, 37.3%, respectively, p=0.027). Compared with control, obesity, obesity + DM, and obesity + CKD groups, CKM patients required significantly more often retrograde crossing (33.2% vs. 28.1%, 31.3%, 30.0%, and 34.2%, respectively; p<0.001). CKM syndrome was also associated with higher prevalence of balloon-uncrossable lesions (12.1% vs. 7.9%, 7.3%, 10.0%, and 8.3%, respectively; p<0.001) and balloon-undilatable lesions (11.7% vs. 4.3%, 4.8%, 7.8%, and 8.5%, respectively; p<0.001). Procedural duration was significantly longer in CKM patients compared with control, obesity, obesity + DM, and obesity + CKD groups (median procedural time: 122 vs. 103, 110, 112, and 114 minutes, respectively; p<0.001) After adjustment, CKM syndrome was not significantly associated with higher risk of MACE (odds ratio [OR] 0.96, 95% Confidence Interval [CI] 0.50–1.83) or with technical success (OR 0.79, 95% CI 0.59–1.50). Conclusion CKM syndrome is associated with higher lesion and procedural complexity in CTO PCI but is not independently associated with technical success or MACE.
Kumar, Sant
( Creighton University
, Phoenix
, Arizona
, United States
)
Khelimskii, Dmitrii
( MESHALKIN NATIONAL RESEARCH CENTER
, Novosibirsk
, Russian Federation
)
Jaffer, Farouc
( MASSACHUSETTS GENERAL HOSPITAL
, Boston
, Massachusetts
, United States
)
Abi Rafeh, Nidal
( STATEN ISLAND UNIVERSITY HOSP
, Staten Island
, New York
, United States
)
Chandwaney, Raj
( OKLAHOMA HEART INSTITUTE
, Tulsa
, Oklahoma
, United States
)
Cevik, Cihan
( TEXAS HEART INSTITUTE
, Houston
, Texas
, United States
)
Ahmad, Yousif
( UCSF
, San Francisco
, California
, United States
)
Mastrodemos, Olga
( MHIF
, Minneapolis
, Minnesota
, United States
)
Rangan, Bavana
( Minneapolis Heart Institute Foundn
, Minneapolis
, Minnesota
, United States
)
Jalli, Sandeep
( Minneapolis Heart Institute
, Minneapolis
, Minnesota
, United States
)
Voudris, Konstantinos
( Allina Minneapolis Heart Institute
, Minneapolis
, Minnesota
, United States
)
Strepkos, Dimitrios
( Minneapolis Heart Institute
, Minneapolis
, Minnesota
, United States
)
Sandoval, Yader
( Minneapolis Heart Institute
, Minneapolis
, Minnesota
, United States
)
Burke, M Nicholas
( Minneapolis Heart Institute
, Mpls
, Minnesota
, United States
)
Brilakis, Emmanouil
( Minneapolis Heart Institute
, Edina
, Minnesota
, United States
)
Alexandrou, Michaella
( Minneapolis Heart Institute Foundat
, Minneapolis
, Minnesota
, United States
)
Mutlu, Deniz
( Minneapolis Heart Institute Foundat
, Minneapolis
, Minnesota
, United States
)
Carvalho, Pedro
( Minneapolis Heart Institute Foundat
, Minneapolis
, Minnesota
, United States
)
Sara, Jaskanwal Deep
( Minneapolis Heart Institute
, Minneapolis
, Minnesota
, United States
)
Ser, Ozgur
( Minneapolis Heart Institute Foundat
, Minneapolis
, Minnesota
, United States
)
Alaswad, Khaldoon
( Henry Ford Hospital
, Detroit
, Michigan
, United States
)
Basir, Babar
( HENRY FORD HOSPITAL
, Detroit
, Michigan
, United States
)
Author Disclosures:
Sant Kumar:DO NOT have relevant financial relationships
| Dmitrii Khelimskii:DO NOT have relevant financial relationships
| Farouc Jaffer:No Answer
| Nidal Abi Rafeh:No Answer
| Raj Chandwaney:DO NOT have relevant financial relationships
| Cihan Cevik:No Answer
| Yousif Ahmad:No Answer
| Olga Mastrodemos:DO NOT have relevant financial relationships
| Bavana Rangan:No Answer
| Sandeep Jalli:No Answer
| Konstantinos Voudris:No Answer
| Dimitrios Strepkos:DO NOT have relevant financial relationships
| Yader Sandoval:DO have relevant financial relationships
;
Consultant:Abbott:Active (exists now)
; Consultant:Roche :Active (exists now)
; Consultant:Philips:Active (exists now)
; Speaker:Medtronic:Active (exists now)
; Speaker:Heartflow:Active (exists now)
; Consultant:Heartflow:Active (exists now)
; Consultant:GE Healthcare:Active (exists now)
; Speaker:Cleerly:Active (exists now)
; Research Funding (PI or named investigator):Cleerly:Active (exists now)
; Speaker:Cleerly:Active (exists now)
; Consultant:Cathworks :Active (exists now)
| M Nicholas Burke:DO have relevant financial relationships
;
Ownership Interest:Egg Medical:Active (exists now)
| Emmanouil Brilakis:DO have relevant financial relationships
;
Consultant:Abbott Vascular:Active (exists now)
; Individual Stocks/Stock Options:Cleerly Health:Active (exists now)
; Ownership Interest:Hippocrates LLC:Active (exists now)
; Consultant:Orbus Neich:Past (completed)
; Consultant:Teleflex:Active (exists now)
; Consultant:SIS Medical:Active (exists now)
; Consultant:Medtronic:Active (exists now)
; Consultant:IMDS:Active (exists now)
; Consultant:Haemonetics:Active (exists now)
; Consultant:GE Healthcare:Active (exists now)
; Royalties/Patent Beneficiary:Elsevier:Active (exists now)
; Consultant:CSI:Past (completed)
; Consultant:Cordis:Active (exists now)
; Consultant:Boston Scientific:Active (exists now)
; Consultant:Biotronik:Active (exists now)
| Michaella Alexandrou:DO NOT have relevant financial relationships
| Deniz Mutlu:DO NOT have relevant financial relationships
| Pedro Carvalho:DO NOT have relevant financial relationships
| Jaskanwal Deep Sara:DO NOT have relevant financial relationships
| Ozgur Ser:No Answer
| Khaldoon Alaswad:DO NOT have relevant financial relationships
| Babar Basir:DO have relevant financial relationships
;
Consultant:Abiomed:Active (exists now)
; Consultant:Zoll:Active (exists now)
; Consultant:Chiesi:Active (exists now)
; Consultant:Boston Scientific:Active (exists now)